132 results on '"Shi, Anhui"'
Search Results
2. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial
3. Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029)
4. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial
5. Clinical association between plan complexity and the local-recurrence-free-survival of non-small-cell lung cancer patients receiving stereotactic body radiation therapy
6. First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
7. Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis
8. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial
9. A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma
10. Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study
11. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
12. Conditional survival and annual hazard of death in elderly patients with esophageal cancer receiving definitive chemoradiotherapy
13. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy
14. Cardiac atlas development and validation for automatic segmentation of cardiac substructures
15. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
16. Radiotherapy Improves Survival of Patients With Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer After Endoscopic Submucosal Dissection
17. Neoadjuvant chemoradiotherapy followed by oesophagectomy may be the optimal treatment option for lower thoracic oesophageal cancer with supraclavicular lymph node metastasis: An inverse probability of treatment‐weighted analysis of SEER database.
18. A prediction model for dosimetric‐based lung adaptive radiotherapy
19. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).
20. Effects of Enteral Nutrition on Patients With Oesophageal Carcinoma Treated With Concurrent Chemoradiotherapy: A Prospective, Multicentre, Randomised, Controlled Study
21. Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT
22. Prediction of Clinical Outcome in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy by Plasma Markers
23. Cone‐beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients
24. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
25. Optimal first‐line treatment for advanced thymic carcinoma
26. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study
27. P2.02-040 Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer
28. Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer
29. Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515).
30. Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial.
31. A randomized phase III trial comparing triple weekly usage with weekly usage of paclitaxel in concurrent chemoradiotherapy for patients with locally advanced non-small cell lung cancer.
32. Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy
33. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy
34. P2-222: Can the patients with locally advanced non-small cell lung cancer (LANSCLC) tolerate 60mg/m2 docetaxel on day 1 and 30mg/m2 Cisplatin on day 1 and 2 for 2 cycles during concurrent radiotherapy (CCRT) after 2-3 cycles of induction chemotherapy?
35. P2-223: Analysis of clinical and dosimetric factors associated with severe radiation pneumonitis in locally advanced Non–Small–Cell–Lung–Cancer patients treated with concurrent chemotherapy and intensity–modulated radiotherapy (IMRT)
36. Phase I study to determine the MTD of paclitaxel given three times per week during concurrent radiation therapy for stage III non-small cell lung cancer
37. Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy.
38. Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy.
39. Can the patients with locally advanced non-small cell lung cancer (LANSCLC) tolerate 60mg/m2 docetaxel on day 1 and 30mg/m2 Cisplatin on day 1 and 2 for 2 cycles during concurrent radiotherapy (CCRT) after 2-3 cycles of induction chemotherapy?
40. Analysis of clinical and dosimetric factors associated with severe radiation pneumonitis in locally advanced Non-Small-Cell-Lung-Cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT).
41. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
42. Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis.
43. Dosimetric comparison of IMPT vs VMAT for multiple lung lesions: an NTCP model-based decision-making strategy.
44. Results of a Pilot External Quality Assessment Scheme for Genetic Testing of Newborns with Spinal Muscular Atrophy.
45. Renin-angiotensin system mechanism underlying the effect of auricular acupuncture on blood pressure in hypertensive patients with phlegm-dampness constitution: Study protocol for a randomized controlled trial.
46. Bioinformatics-aided Protein Sequence Analysis and Engineering.
47. [Application of Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Locally Advanced Non-small Cell Lung Cancer].
48. A facile methodology using quantum dot multiplex labels for tracking co-transfection.
49. Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer.
50. Effect of Coriolus versicolor glucan on the stimulation of cytokine production in sarcoma-180-bearing mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.